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Background: Several quantitative approaches for benefit-harm assessment of health care interventions exist but it
is unclear how the approaches differ. Our aim was to review existing quantitative approaches for benefit-harm
assessment and to develop an organizing framework that clarifies differences and aids selection of quantitative
approaches for a particular benefit-harm assessment.
Methods: We performed a review of the literature to identify quantitative approaches for benefit-harm assessment.
Our team, consisting of clinicians, epidemiologists, and statisticians, discussed the approaches and identified their
key characteristics. We developed a framework that helps investigators select quantitative approaches for
benefit-harm assessment that are appropriate for a particular decisionmaking context.
Results: Our framework for selecting quantitative approaches requires a concise definition of the treatment
comparison and population of interest, identification of key benefit and harm outcomes, and determination of the
need for a measure that puts all outcomes on a single scale (which we call a benefit and harm comparison metric).
We identified 16 quantitative approaches for benefit-harm assessment. These approaches can be categorized into
those that consider single or multiple key benefit and harm outcomes, and those that use a benefit-harm
comparison metric or not. Most approaches use aggregate data and can be used in the context of single studies or
systematic reviews. Although the majority of approaches provides a benefit and harm comparison metric, only four
approaches provide measures of uncertainty around the benefit and harm comparison metric (such as a 95 percent
confidence interval). None of the approaches considers the actual joint distribution of benefit and harm outcomes,
but one approach considers competing risks when calculating profile-specific event rates. Nine approaches
explicitly allow incorporating patient preferences.
Conclusion: The choice of quantitative approaches depends on the specific question and goal of the benefit-harm
assessment as well as on the nature and availability of data. In some situations, investigators may identify only one
appropriate approach. In situations where the question and available data justify more than one approach,
investigators may want to use multiple approaches and compare the consistency of results. When more evidence
on relative advantages of approaches accumulates from such comparisons, it will be possible to make more specific
recommendations on the choice of approaches.* Correspondence: mpuhan@jhsph.edu
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Some decisions on health care interventions are straight-
forward because the benefits clearly outweigh the harms
or vice versa. Many decisions, however, require careful
balancing of the benefits and harms. For example, in
order to decide on the use of aspirin for the prevention
of myocardial infarction, one would typically consider
the risk reduction for myocardial infarction over a cer-
tain period of time (e.g. 10 years) as well as the increased
risks for hemorrhagic stroke and gastrointestinal bleeding
[1]. One would also need to consider that the benefit-
harm comparison varies across patients since the risks for
these outcomes and absolute treatment effects depend
much on an individual patient’s profile including her or
his preferences. Sometimes, the decisionmaking context is
even more complex than for aspirin. Tamoxifen for the
prevention of breast cancer, for example, modifies the risk
not only for breast cancer, but also for endometrial car-
cinoma, bone fractures, pulmonary embolism, stroke and
cataracts [2]. As with aspirin, the benefit-harm compari-
son of tamoxifen depends on a woman’s profile, which in
this case includes age, the risk for invasive breast cancer,
race and whether the uterus is intact or has been
removed [3].
In situations where multiple outcomes, patient profiles
and also patient preferences need to be considered, it is
challenging to compare benefits and harms without a
quantitative approach. Without a quantitative approach,
it is not verifiable if and how different outcomes, patient
profiles, patient preferences, and sources of evidence
were considered and weighted. Non-quantitative assess-
ments of benefits and harms may lead to inappropriate
decisions for or against treatments. This lack of trans-
parency may be less problematic in an individual deci-
sionmaking context, but it seems unacceptable when
major regulatory decisions or clinical guideline recom-
mendations are at stake. A number of quantitative
approaches have been developed and applied to handle
the multidimensionality of a benefit-harm assessment
[3-8]. But there is little guidance on the selection of an
appropriate quantitative approach for a particular clin-
ical question in a benefit and harm assessment [5,7,9].
Past reviews of quantitative approaches for benefit and
harm assessment have not organized methods according
to important characteristics [5,7,9]. A framework that
recognizes their important characteristics and organizes
them accordingly could be a step forward to understand-
ing the common and different elements of existing
approaches, to guide their further development, and sup-
port investigators, who plan to conduct a quantitative
benefit and harm assessment, in their choice of approach.
Such an organizing framework could be particularly
attractive for organizations or investigators who conduct
or use systematic reviews because the literature is mostlysilent about the use of quantitative benefit and harm
assessment approaches in the context of a systematic
review. Familiarity with available approaches and their
key characteristics will help systematic reviewers to de-
velop protocols that specify all sources and types of
data needed for benefit-harm assessments. For ex-
ample, additional database searches may be needed to
identify evidence on baseline risks, harms or patient
preferences that would be missed by standard searches
that commonly focus on randomized trials. Therefore,
our aim was to review existing quantitative approaches
for benefit-harm assessment and to develop an organ-
izing framework that helps understanding of differ-
ences among methods and their selection for a specific
clinical question.
Methods
Scope of the literature review
Our purpose was to review quantitative approaches for
benefit and harm assessments that use formulas or
graphical displays to compare the benefits and harms.
We evaluated methods feasible for use in systematic
reviews or to use the data synthesized in systematic
reviews. We did not consider theoretical frameworks
and qualitative approaches for benefit and risk assess-
ment, nor approaches that have not been used in the
medical field. It is important to note that our review fo-
cused on quantitative assessment and not on the entire
process of a benefit-harm assessment (e.g. in the context
of a new drug approval) that includes quantitative and
qualitative processes [10,11]. Also, we did not review
approaches for making treatment recommendations for
populations or individual patients because this requires
consideration of specific health care contexts, costs of
treatment, and other contextual factors, which is beyond
the scope of most systematic reviews.
Review of the literature
We began our search for quantitative benefit and harm
approaches with key articles culled from the investiga-
tors’ reference libraries, including prior work on
approaches for assessing benefits and harms. We looked
for articles that were written for quantitative benefit and
harm assessment, which included consideration of at
least one outcome for both benefit and harm of a med-
ical or public intervention. We included approaches that
analyzed benefit and harm outcomes entirely separately
as well as approaches that provided a benefit and harm
comparison metric where single or multiple benefit and
harm outcomes are put on the same scale, which we will
call the benefit-harm comparison metric (e.g. Quality-
adjusted Life Years [QALYs] or probability scale). We
screened the reference lists of all included articles for
more relevant articles. The group then discussed each
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below. We also reviewed the manuals of the Evidence
Based Practice Center program of the Agency for
Healthcare Research and Quality (AHRQ) (http://www.
ahrq.gov/clinic/epc/) and of the Cochrane Collaboration.
We did not perform a formal systematic review of the
literature because a review on the topic of quantitative
benefit and harm assessment already existed [5] and
because our focus was on organizing available
approaches. We capitalized on the work done to create
a list of relevant approaches [5], which allowed us to
devote adequate resources to the main focus of devel-
oping an organizing framework that helps understand-
ing the differences among methods and their selection
for a specific clinical question.
Defining the decisionmaking context of a benefit and
harm assessment and identification of key characteristics
of existing quantitative approaches for benefit and harm
assessment
Our team, consisting of clinicians, epidemiologists and sta-
tisticians, discussed the identified quantitative approaches
for benefit and harm assessment and the context in which
they might be used in 12 one-hour sessions. The discussion
served to define properties that characterize quantitative
approaches for benefit and harm assessments. Based on
these characteristics we developed a simple algorithm that
may guide investigators, systematic reviewers, guideline
developers or policymakers in their selection of a quantita-
tive approach for benefit-harm assessment. We iteratively
defined key characteristics with which existing quantitative
approaches for benefit and harm assessment can be
described and that allow comparisons across quantitative
approaches. We also recorded limitations inherent to each
of them that may threaten their usefulness or limit their
applicability for certain questions of benefit and harm. In
addition, we prepared examples for quantitative
approaches for benefit-harm assessment that would high-
light differences between them.
Results
Decisionmaking context of benefit and harm assessment
We identified three characteristics of a decisionmaking
context that need to be defined. First, the treatment com-
parison and population for which the benefit-harm assess-
ment is made should be characterized. The comparison of
interest can be an intervention versus no intervention or
an intervention A versus an intervention B. A population
can be broadly defined, for example as a screening or pri-
mary prevention population, or be restricted to a particu-
lar setting (e.g. primary care) or a particular clinical
population (e.g. patients with manifest coronary heart dis-
ease). Secondly, the key benefit and harm outcomes of
interest for which the evidence and the benefit-harmcomparison is sought should be identified. The figure
shows that there might be a single benefit and a single
harm outcome that are of interest, or there could be mul-
tiple outcomes. As is noted in literature on the more gen-
eral processes of assessing the benefits and harms of
interventions in guidelines and systematic reviews,
patient-important outcomes might be preferred as key
outcomes but, sometimes, a surrogate outcome may be
considered if there is a strong correlation with patient-
important outcomes or if no evidence on patient-
important outcomes is available. Finally, one should decide
whether a benefit-harm comparison metric is desired that
puts all outcomes on a common scale so that a single
number will inform about the comparison of benefits and
harms. The decisionmaking context is likely to be import-
ant to decide on the need for a benefit-harm comparison
metric because the output of the available quantitative
approaches differ substantially and may not be appropriate
for all decisionmakers such as patients and their health
care providers, clinical or public health guideline develo-
pers, regulatory agencies, policymakers, or payers.Overview of existing quantitative approaches for
benefit-harm assessment
We identified 16 approaches, which can be grouped into
two broad categories (Figure 1): One category comprises
simpler approaches that typically deal with a single out-
come for benefit (e.g. prevention of myocardial infarction)
and one outcome for harm (e.g. gastrointestinal bleeding).
The single benefit and harm can, however, also be compos-
ite outcomes (e.g. cardiovascular events) that summarize
several outcomes (acute coronary syndrome, stroke, and
cardiovascular death). The more complex approaches con-
sider multiple outcomes for either benefit or harm, or both.
Of note, although some approaches like the Number
needed to treat (NNT) [12,13] and Number needed to
harm (NNH) and (Quality-adjusted) Time without Symp-
toms and Toxicity (Q- TWiST) [14,15] are mostly used
when there is a single benefit and a single harm outcome.
Researchers can use these approaches separately for differ-
ent outcomes in situations where multiple outcomes are
important (e.g. multiple NNTs and NNHs). In the figure,
we categorized approaches according to how they are typ-
ically used in the medical literature (e.g. NNT and NNH
are typically used for single outcomes), but listed a few of
them in two categories if we could not clearly categorize
them (e.g. Minimum Target Event Risk for Treatment
[MERT], (Quality-adjusted) Time without Symptoms and
Toxicity).
The figure shows that the use of a benefit and harm
comparison metric further distinguishes various
approaches. The number of outcomes, the need for a
benefit and harm comparison metric, and the quality
Outcomes for which 
the evidence is sought and summarized  
Single outcome for benefit and 
single outcome for harm
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Figure 1 Key characteristics of the benefit-harm question that may guide selection of quantitative assessment for benefit-harm
assessment. Abbreviations: INHB, Incremental net health benefit; MCE, Minimum clinical efficacy; NCB, Net Clinical Benefit; NNT, Number needed
to treat; NNH, Number needed to treat for harm; Q-Twist, (Quality-adjusted) Time without Symptoms and Toxicity: RBC, Risk–benefit contour;
RV-NNT, Relative value adjusted number needed to treat; QFRBA, Quantitative Framework for Risk and Benefit Assessment; TURBO, Transparent
Uniform Risk Benefit; BLRA, Benefit-less-risk analysis; PSM, Probabilistic simulation methods; MERT, Minimum Target Event Risk for Treatment;
MCDA, Multicriteria decision analysis: RBP, Risk–benefit plane; SPM, Stated preference method; MAR, Maximum acceptable risk.
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come is of interest or when multiple outcomes are treated
separately. Multicriteria decision analysis (MCDA) [16,17]
andtheGail/NationalCancer Institute [3]approachprovide
examples for approacheswheremultiple outcomes are con-
sideredandputonabenefit-harmcomparisonmetric.
Description of key characteristics of 16 quantitative
approaches for benefit-harm assessment
We focus here on additional key characteristics that en-
able researchers to understand the similarities and differ-
ences and choose the appropriate approaches for their
benefit-harm question and context. Papers focusing on
each individual approach have described in detail the 16
approaches although not in the context of systematic
reviews [5].
We identified the following additional key characteristics:
1. The type of data needed: Individual patient data have
advantages over aggregate data typically available
for evidence synthesis. In an individual study,
information on the co-occurrence of benefit and
harm outcomes is available for each patient. An
important consequence of the availability of such
individual data is that researchers can consider
the joint probability of benefit and harm
outcomes.2. The type of analyses: Analyses for benefit-harm
assessment could include any type of statistical
analysis. There is a major distinction, however,
between approaches that are data driven
(deterministic) and approaches that use modeling
(stochastic) where data are not described by unique
values, but rather by probability distributions.
3. The type of benefit-harm comparison metric:
Researchers may use absolute and relative metrics as
well as QALYs.
4. Assumptions: In benefit-harm analyses researchers
need to make a number of assumptions. For example,
if researchers use a benefit-harm comparison metric,
the assumption is that it is justifiable that outcomes
are combined on a single scale. Other assumptions
relate to the joint occurrence of separate outcomes.
Some approaches assume that separate outcomes
occur independently, which may be justifiable in
some instances.
5. Consideration and incorporation of patient
preferences: Some quantitative approaches explicitly
consider patient preferences for different outcomes
in order to weight the benefits and harms.
6. Types of presenting benefit risk comparisons:
Researchers can use various formats to present the
results of a quantitative benefit-harm assessment.
Researchers may present the benefit-harm
comparison as a difference in the number of events
between a treatment or no treatment, or as a ratio.
They may also express the comparison by the time
gained or lost without symptoms through a
treatment. Or, researchers can use graphics that
Table 1 Examples for quantitative approaches for benefit-harm assessment
NNT and NNH Examples where researchers consider single benefit and harm outcomes with or without a benefit-harm comparison
metric
NNT and its harm outcome counterpart, NNH, are the approaches researchers most widely use to measure risk and benefit
reported in systematic reviews and evidence-based medicine [12,13]. Also, NNT is the metric clinical practice guidelines most
commonly use to address benefit-harm comparisons. NNT or NNH are the number of individuals who need to be treated over
a specified period of time for one person to benefit or be harmed, respectively, and vary as the specified treatment time
varies. Studies mostly present NNT and NNH separately (i.e. they are not combined on a benefit-harm comparison metric such
as the ratio of NNT and NNH). For example, the Based Clinical Practice Guidelines on Antithrombotic Therapy in Atrial
Fibrillation of the American College of Chest Physicians present NNTs based on a systematic review of randomized trials of
oral anticoagulant therapy versus no antithrombotic therapy: “The efficacy of warfarin was consistent across studies with an
overall relative risk reduction of 68 percent (95 percent confidence interval [CI], 50 to 79 percent) analyzed by intention-to-
treat [18]. The absolute risk reduction implies that 31 ischemic strokes will be prevented each year for every 1,000 patients
treated (or 32 patients needed to treat for 1 year to prevent one stroke, NNT = 32)”.In contrast, studies scarcely use the NNT/
NNH ratio. One reason for the rare application of this benefit-harm comparison metric may be that investigators or guideline
developers are reluctant to weigh benefit and harm outcomes equally on the same scale because of uncertainty about their
relative clinical importance. To address this dilemma, Guyatt et al. proposed using relative value units to weight the NNT or
NNH [19]. An example using the NNT/NNH ratio is a review of trials of an antidepressant drug which summarized benefit
defined as response and remission of depression and harm as suicide [20].
Multicriteria
decision analysis
Example where multiple benefit and harm outcomes and preferences are considered
The Analytic Hierarchy Process A is a commonly used approach for MCDA studies is. We illustrate this approach using the
comparative effectiveness review of oral hypoglycemic agents for type 2 diabetes. The first step in Analytic Hierarchy Process
analysis consists of defining the goal of the decision, the alternatives being considered, and the criteria that determines how
well patients and clinicians can expect that alternatives will meet the goal [4,21]. The criteria are organized into a hierarchical
decision model with a desired goal of determining the best treatment of type 2 diabetes at the top; the alternatives
thiazolidinediones, metformin, and sulfonylurea’s at the bottom; and the criteria in between. Operationally, we could define
two criteria as being necessary for determining the best treatment: 1) its ability to maximize benefits via glucose reduction,
and 2) its ability to minimize harms or medication-related adverse effects. Researchers could divide the criteria on maximizing
benefits into three sub-criteria: health-related quality of life, microvascular benefit (such as improvements in incidence of
neuropathy, nephropathy and diabetic retinopathy), and potential macrovascular benefit. Researchers could subdivide the
criteria on minimizing risk of harm into six sub-criteria based on medication-related adverse events: congestive heart failure,
fractures in women, macular edema, bladder cancer, myocardial infarction, and hypoglycemia. In the second step, researchers
obtain information about how well the alternatives can be expected to fulfill the decision criteria from a systematic review.
The third step consists of two parts: 1) comparing the ability of the alternative treatments to fulfill the prespecified criteria
(maximizes benefit and minimizes harm) using standard Analytic Hierarchy Process pairwise comparisons, and 2) assessing the
importance of these criteria to the decision goal. In the fourth step, researchers can combine the scales created in step 3 to
create a summary score (the benefit-harm comparison metric) indicating how well the alternative treatments can be expected
to meet the decision goal [21]. The fifth step consists of performing sensitivity analyses to explore the effects of changing the
estimates or judgments used in the original analysis. The main advantage of MCDA is that it is that identifies the extent to
which every criterion, judgment, and weight contributes to the benefit-harm comparison metric and that it also incorporates
uncertainty. Additional visual representation of the results allow one to gain understanding and articulate the divergence
between relevant stakeholders [4].
Gail/National
Cancer Institute
Example where multiple benefit and harm outcomes are considered with a benefit-harm comparison metric
Some decisionmaking contexts are more complicated because there are many potential treatment outcomes as well as
sources of uncertainty. A well known example of a very challenging decision is whether or not to use of tamoxifen to prevent
breast cancer. Tamoxifen reduces the risk for invasive and in situ breast cancer substantially and prevents some bone fractures
[2]. On the other hand, it increases the risk for endometrial cancer, stroke, and pulmonary embolism. The National Cancer
Institute under the leadership of Gail developed an approach to deal with multiple outcomes [3]. Rather than simplifying the
benefit-harm assessment to single outcomes, as many investigators and guideline developers do, they estimated the
probability of various outcomes for women with and without tamoxifen therapy over a period of 5 years. Based on
observational studies, surveillance registries or placebo arms of randomized trials, they first estimated the expected number of
invasive breast cancers, in situ breast cancers, hip fractures, endometrial cancers, strokes, pulmonary embolisms, deep vein
thromboses, colles’ fractures, spine fractures, and cataracts each per 10,000 women, over 5 years, in the absence of tamoxifen
treatment. They estimated these numbers overall and stratified for different age and race categories. Then, based on the
Breast Cancer Prevention Trial, they estimated, for each outcome, the expected number of the same outcomes but with
tamoxifen treatment. Again this was per 10,000 women over 5 years, as well as overall, and it was stratified for different age
and race categories. They also took competing risk from death into consideration. In order to put all outcomes on the same
scale but to also consider the relative clinical importance of these outcomes, they categorized the outcomes into life-
threatening, severe and other outcomes and suggested weighting them with some factor (e.g. 1 for life-threatening, 0.5 for
severe and 0.0 for other outcomes). These categories and weights can be modified according to patient or treatment provider
preferences. Ultimately, the results of the benefit-harm assessment are presented as the net number of events prevented or in
excess per 10,000 women treated with tamoxifen over a period of 5 years. For example, for a 45-year-old woman with a
uterus and a 4 percent risk of invasive breast cancer over 5 years, the net number of events prevented (weighted by their
clinical importance) is 196 per 10,000 women with this profile (the expected number of prevented invasive and in situ breast
cancers was 299/10,000 woman but there were 59 women/10,000 woman with harm such as endometrial cancer, stroke,
pulmonary embolism, or deep vein thrombosis). The net benefit (benefit minus harm events) varied considerably and was
positive for some profiles (as example above) but negative for others (e.g. black woman with age 50–59 years and a 5-year
risk of invasive breast cancer of 4 percent).
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Table 3 Brief description of the 16 approaches for quantitative benefit-harm assessment
Benefit-less-risk
analysis (BLRA)
Researchers developed benefit-less-risk analysis, which combines benefit and harm into a single metric, primarily for clinical
trials [36]. This analysis takes advantage of individual patient data. For each patient, researchers record the benefit (yes or no)
and express the harm as a value between 0 and 1. Researchers present the relationship between benefit and risk as risk
subtracted from benefit, which allows for statistical testing of comparisons between treatment groups. Patient preferences
expressing the relative importance of benefit and harm outcomes can be considered. Benefit-less-risk analysis is a method that
takes advantage of individual patient data. Thus, if researchers applied this method in a systematic review, they would need to
gather individual patient data from the primary studies.
Boers’ 3x3 table This quantitative approach does not require any statistical models but suggests a way of organizing outcome data on the
same scale [23]. Researchers need individual patient data. They split the outcomes of patients into three categories and
display the number of patients with a certain benefit-harm profile (e.g. major benefit and minimal harm) in a 3x3 table.
Researchers do not consider treatment effects directly since they construct separate 3x3 tables for each treatment group. As a
consequence, no measures of uncertainty are available. Researchers do not consider patient preferences, but instead the
clinicians’ view or agreement of what constitutes minimal, moderate, or major benefit or harm. The method is both feasible
for single trials or systematic reviews. A disadvantage is that, although each table is simple and easy to read, it requires
readers to somehow estimate treatment effects across tables or to provide a benefit and harm comparison metric, and thus
challenges rather than facilitates conclusions concerning benefits and harms.
Gail/National
Cancer Institute
This is one of the most comprehensive approaches for benefit and harm assessment and considers various data sources to
balance the benefits and harms of a treatment [3]. As described above, researchers can calculate the benefit and harm
comparison metric as the sum of benefit and harm outcome rates per patient profile. They can incorporate patient
preferences by looking only at one severity grade, or by putting weights on outcome rates that reflect patient perception of
events: very severe, severe, or moderately severe. The approach does not consider the joint distribution of benefit and harm
outcomes but could potentially be extended to do so. However, by looking at benefit and harm comparison estimates across
patient profiles, one gets an impression of how the net benefit changes, even qualitatively, as the baseline risk changes. This
approach is resource intensive because it considers multiple data sources and multiple outcomes. The United States
Preventive Services Taskforce used a similar though simplified approach to make recommendations on the use of aspirin for
the prevention of myocardial infarction [1]. Similar to the tamoxifen example, researchers estimated the number of benefit
(myocardial infarction) and harm (bleedings) events per 1,000 men or women based on observational data and the evidence
on treatment benefits and combined harms with these outcome estimates. The benefit-harm comparison metric provided the
number of net events (benefit minus harm) prevented or in excess when aspirin is used [1].
Incremental net
health benefit
Incremental net health benefit provides a benefit and harm comparison metric, using QALYs to place one or more benefits
and harms on the same scale, and calculates the difference between benefit and harm between treatments (thus a result >0
is favorable) [24,25]. A key requirement for this approach is the valid measurement of utilities or the sometimes inaccurate
transformation of quality of life scores into utilities. Also, it is often difficult to distinguish between the effects of benefits and




A multi-criteria decision analysis allows for a systematic decisionmaking in complex situations involving tradeoffs, by
considering various harms and benefits associated with treatments [16,17]. Researchers develop a decision tree model to
incorporate benefits from clinical trials and harms such as adverse effects. It allows for input from various stakeholders who
may assign different preference weights to the risks and benefits. MCDA represents an approach to reduce the
multidimensionality of benefit-harm assessment in a systematic way and makes judgments explicit and transparent. It allows
for decisionmaking in the presence of uncertainty and can incorporate data from multiple sources including systematic
reviews. The challenges of its application to systematic reviews include getting reliable information on various preferences,
agreement on all relevant important benefits and harms and the relative importance and weighting of these outcomes, and
the need to specify a decision context since systematic reviews are usually conducted to meet the needs of multiple
decisionmakers. The flexibility of MCDA also poses challenges for benefit-harm assessment as systematic reviews are unable to
inform on all inputs, especially less tangible inputs (e.g. societal values, opportunity costs) that may alter harm and benefit
balance in a particular decision context.
Minimum
clinical efficacy
Minimum clinical efficacy incorporates harm and benefit into a benefit and harm comparison metric. The benefit is the
difference in efficacy and harm, both of which are expressed on a probability scale by applying relative risks reductions
(treatment benefits) and increases (harms) to absolute probabilities as observed in untreated groups [6,27]. Researchers
consider the intervention as having minimal clinically efficacy if the difference between benefit and harm is positive or above
a minimally acceptably threshold. Minimum clinical efficacy can consider relative utilities. A limitation includes the inability to
provide uncertainty estimates for the benefit and harm comparison metric.
Net clinical
benefit
Similar to the Gail/National Cancer Institute approach, the calculation of the net clinical benefit considers different data
sources such as randomized trials, observational studies, and patient preferences, and provides profile-specific benefit-harm
comparison estimates [28]. Researchers calculate the benefit-harm comparison metric as the sum of all expected benefits
minus the sum of all expected harms. They calculate the benefit from the pooled relative risk reductions (based on meta-
analysis) that they apply to patients at different risk for the benefit outcome (e.g. stroke). They calculate the expected harm
from the risks for the harm outcome, and the patient preferences for the harm outcome. They calculate net clinical benefit
using a Bayesian approach where they model all steps simultaneously (meta-analysis, calculation of expected benefit, and
expected harm). A major advantage of this approach is its flexibility to combine different data sources and place distributions
on each parameter. Thereby researchers can qualify uncertainty around the parameters. Net clinical benefit considers patient
preferences for different outcomes, but similar to other approaches, the selection of particular values for preferences has a
large impact on the net clinical benefit estimates. In the Figure, we categorized the approach as considering only single
benefit and harm outcomes because published applications of the approach considered only one benefit and one harm
outcome. But the approach offers, theoretically, enough flexibility to consider multiple outcomes.
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The (NNT) NNH) refer to the number of individuals who need to be treated over a specified period of time with the
intervention for one person to benefit and experience the harm [12,13].NNT and NNH depend on baseline risk (and are thus
sensitive to different patient profiles) and the degree of relative risk reduction provided by the intervention (which researchers
often assume is constant across the disease spectrum, but in fact may actually vary). Researchers can calculate NNT and NNH
for single outcomes (e.g. NNT for exacerbations vs. NNH for fractures) or for composite outcomes for both benefit and harm.
But since the concept of NNT is one of frequency and not of importance, researchers should only calculate the NNT and NNH
ratios or differences for outcomes of similar importance [37]. When researchers calculate a ratio or difference between NNT
and NNH as a benefit and harm comparison metric, researchers assume their independence and may need to extrapolate so
that the ratios refer to the same time period. Researchers cannot calculate NNT and NNH for continuous outcomes unless
such outcomes are dichotomized. NNT and NNH is perhaps the most widely used measure of risk and benefit reported in
systematic reviews and evidence-based medicine. Extensions of the NNT/NNH ratio approach include: the threshold NNT, the
minimum target event risk for treatment (MERT), and the subject-year adjusted NNT [8]. The threshold NNT reflects the point
at which the risks and costs of a clinical intervention balance the benefit, and the minimum target event risk for treatment
defines the minimum target event risk at which the intervention is justified. Subject-year adjusted NNT uses subject years as
the denominator instead of participants, to better account for time-on-treatment for participants. For example, if there are two
events per 1,000 subject years in the control group and one event per 1,000 subject years in the intervention group, the NNT
is 1,000 subject years. This means that with treatment, one fewer event would occur with every 1,000 subject-years. Methods
for providing uncertainty for these benefit and harm comparison metrics are available [8]. The NNT/NNH, threshold NNT and




The PSM use probabilistic simulations for benefit and harm comparison estimates using Monte Carlo methods. PSM can
incorporate parameters from multiple data sources (systematic reviews of randomized clinical trials and observational studies),
patient preferences (e.g. from conjoint analysis) and different patient profiles [7,29,32].This method estimates uncertainty
around the benefit and harm comparison estimate, with or without consideration of the joint distribution of benefits and






QFRBA reports on benefit and harm separately. It does not provide a benefit and harm comparison metric and uncertainty
estimates for benefit or harm outcomes are only available for the separate treatment effects [5]. An advantage of this method
is that keeps benefit and harm separate, leaves room for incorporation of preferences by decisionmakers and consideration of








TWiST compares treatments in terms of the time without symptoms gained versus the time lost due to the experience of
adverse effects [14,15]. It therefor puts the benefit and harm on the same scale (time). Q-TWiST is a further development
where time is converted into QALYs [30]. Here the benefit and harm comparison metric is the difference between the drug
associated gain in QALYs and the loss in QALYs associated with the treatment due to adverse effects. Numerous oncology
studies have used Q-TwiST. The major advantage of this method is the ability to incorporate patient preferences, which may
change over time. The method depends heavily on the availability of measurements that allow estimating the length of time
periods without symptoms and of time periods where adverse effects are experienced. Also, measurement instruments need
to be highly specific so that a distinction between benefit and harm is possible. For example, quality of life and some
preference-based instruments often provide a composite score that already synthesizes the overall experience of a patient.
Also, QALYs itself values health states rather than changes in health states, and lack of a measure of uncertainty around these
measurements may limit the usefulness of this method. In a systematic review, this method may be difficult to apply since
QALYs associated with benefit and harm are unlikely to be reported in reports of primary studies.
Risk–benefit
Contour (RBC)
The risk–benefit contour plot is a graphical method to assess benefits and harms [31]. It portrays the probability of benefit for
a new treatment compared to another treatment against the probability of harm for that new treatment (again as compared
to another treatment). Contour lines portray the shape of this relationship for a number of different probabilities and
confidence levels. The risk-benefit contour plot is a way to express uncertainty associated with certain pairs of benefit and
harm. The plot conveys study-level relationships, and does not consider the dependence of the probability of benefit and
harm at the individual level. Though the method does not incorporate weights (representing patient preferences) for each
type of outcome, researchers could adapt it to do so. Researchers should probably view risk–benefit contour as a way to
present data and visualize uncertainty. This way researchers can base the underlying analyses that yield the probability






The RBP and RBAT display in a simple figure, both separate estimates of benefit and harm and a benefit and harm
comparison metric [29,32]. This method does not consider the individual-level dependence between benefit and harm. Using
an absolute scale, this method plots the probability of benefit (from a comparison between two treatments) against the
probability of harm. With this method, researchers refer to the slope created by a line between the origin and the two-







The major advantage of RV –NNT over NNT and NNH is that it allows for incorporation of preferences into the assessment of
benefit and harm [6,27]. Otherwise it offers the same advantages as the NNT/NNH ratio approach, and suffers from some the






Researchers use SPM and MAR are used to survey patients on how much burden from adverse effects, or serious adverse
events, they are willing to accept in order to experience the benefits of treatment [33,35,38,39]. Researchers need individual
patient data for these approaches. The typical method to elicit preferences is discrete choice or conjoint analysis, where
respondents have to pick their preferred treatment from two treatment scenarios that characterize the benefit and harm of
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Table 3 Brief description of the 16 approaches for quantitative benefit-harm assessment (Continued)
these treatments. These approaches assume that the attractiveness of a particular treatment is a function of the benefit and





The TURBO diagram displays the factors R and B. R is the sum of the most serious adverse effect (scored from 1–5) and the
second most serious adverse effect (scored from 1–2) [11]. Researchers base the scores on the frequency and severity of the
harm outcome. Similarly, factor “B” is the sum of the primary benefit (1–5), and the ancillary benefit (1–2) and researchers base
the scores on the probability and extent of the benefit outcome. The T score represents the benefit and harm comparison
metric and ranges from 1 (high R and low B score) to 7 (high B and low R score).Researchers typically use the TURBO diagram
in a regulatory context (e.g. European Medicines Agency) and therefore, they base them on single trials, but researchers can
also base them on systematic reviews. Researchers can base the factors R and B on absolute or relative measures of treatment
effects for which uncertainty estimates are available. But there is no uncertainty estimates for the benefit and harm
comparison metric (i.e. the “T” score). Unlike other approaches, the TURBO diagram explicitly considers not only one but two
outcomes for both benefit and harm that are weighted differently (up to 2 or 5 points). Challenges to applying the TURBO
method include arbitrary selection of the two benefit and harm outcomes from a comprehensive list of outcomes and the
way researchers assign scores (combining frequency and importance of outcomes).
Puhan et al. BMC Medical Research Methodology 2012, 12:173 Page 9 of 12
http://www.biomedcentral.com/1471-2288/12/173depict the benefit-harm comparison for patients at
different outcome risks or based on other patient
characteristics.
In Table 2, we compare each of the 16 approaches
against these key characteristics. Table 3 provides a more
detailed discussion of each approach. Three approaches
require individual patient data (Table 2) whereas 13
approaches do not require individual patient data. This
means that, although most quantitative approaches were
developed for use in randomized trials and observational
studies, researchers can also use most of these approaches
at the synthesis stage (systematic reviews). Fourteen of
the approaches are data driven but four of them may also
use simulation. One approach (Probabilistic Simulation
Methods [PSM]) is entirely based on simulation. Twelve
of the 16 approaches put benefit and harm outcomes on
the same scale to provide a benefit and harm comparison
metric. Only four approaches provide measures of uncer-
tainty around the benefit and harm comparison metric.
Four approaches could consider the joint distribution of
benefit and harm outcomes for the estimation of uncer-
tainty. But many examples using these four approaches
do not consider the dependence between benefit and
harm, but only consider their marginal distributions (i.e.
consider them to be independent,). Five approaches use
composites outcome for benefit and composite outcomes
for harm while 12 approaches use multiple outcomes.
Researchers have adapted or potentially could adapt nine
of the 16 approaches to incorporate patient preferences.
Discussion
The main finding of our review of quantitative approaches
for benefit and harm assessment used in the medical litera-
ture is a simple algorithm that categorizes existing quanti-
tative approaches broadly into approaches that consider
single or multiple benefit and harm outcomes and into
approaches that use a benefit-harm comparison metric or
present outcomes side by side. We also found that for
most approaches, researchers use aggregate data so as tomake the approaches suitable for systematic reviews even
if that is not their intended purpose. Interestingly, only few
approaches provide measures of uncertainty and none of
the approaches considers a potential correlation between
benefit and harm outcomes (joint distribution).
We identified a number of assumptions that researchers
make when applying some of the quantitative approaches:
First, for some approaches researchers assume that one or
more benefit and harm outcomes can be put on the same
scale to calculate a benefit and harm comparison metric.
Challenges for putting different outcomes on the same
scale include their relative importance to decisionmakers,
simplification of the outcomes (e.g. dichotomizing con-
tinuous outcomes, which may lead to substantial loss of
information), or different methods and timing in the as-
certainment of different outcomes.
However, the advantages of a benefit-harm comparison
metric may be substantial, for example, in the context of
complex situations where multiple outcomes are import-
ant and where patient, provider, and policymaker prefer-
ences vary [7]. It is a great cognitive challenge to process
such a multidimensional task without a benefit-harm
comparison metric. The major advantage of using a
benefit-harm comparison metric (over using an approach
without such a common metric) is that it can make expli-
cit assumptions about the relative importance of outcomes
or the arbitrary selection of the evidence on benefits and
harms or on baseline risks, and that sensitivity analyses
can provide evidence as to how the benefit-harm compari-
son changes if different assumptions are made. Also, a sin-
gle number may provide some advantages for the
communication of benefit-harm comparison to patients
because it avoids overwhelming the patients with data on
multiple different outcomes.
Second, we were surprised to see that there were no
quantitative approaches that considered or even dis-
cussed the joint distribution of benefit and harm out-
comes, even when individual patient data were available.
The joint distribution describes the correlation between
benefit and harm outcomes. Trial reports commonly
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benefit and harm outcomes separately, but rarely de-
scribe the joint distribution of the effects of the treat-
ment on the benefit and harm outcomes. Without the
joint distribution of all the effects, we have to assume in-
dependence of the benefit and harm effects. This may
not yield a valid estimate of the uncertainty of the
benefit-harm balance metric. Changes in reporting prac-
tices, such as online journal appendix materials or online
repositories of covariance data for later data synthesis,
could address this limitation. Systematic reviewers
should keep in mind the limitation of not considering
the joint distribution when interpreting results from a
quantitative benefit and harm assessment.
The figure and table show a number of characteristics
that help distinguish various existing quantitative
approaches. While these characteristics are important for
the selection of an appropriate quantitative approach,
there are a number of additional considerations that
researchers need to make because they have implications
regarding the type of evidence included in the benefit-
harm assessment. For example, clinical trials are com-
monly designed to provide high-quality evidence and suf-
ficient power for benefit outcomes. Harms often receive
much less attention in terms of accurate and valid meth-
ods of measurement [40]. Such asymmetry in the quality
of outcome ascertainment affects the validity of a quanti-
tative benefit and harm assessment, but it is yet unclear
how to downgrade the quality of evidence for this reason.
In contrast to the framework developed here that fo-
cused entirely on the quantitative assessments, Lynd and
others developed criteria that apply to the entire process
of a benefit-harm assessment. This usually requires that
researchers consider both quantitative and qualitative
approaches to make conclusions regarding benefit-harm
comparisons of health care interventions [10,11,41,42].
Lynd and others proposed 10 criteria for benefit-harm
assessments--be universal, inclusive, comprehensive, pa-
tient-sensitive, easily interpreted consider preferences,
define when benefits outweigh harms, incorporate uncer-
tainty, be flexible and integrate economic evaluations)
[41]. We agree with these guiding principles but also think
that researchers cannot readily use them to judge the ad-
equacy of specific quantitative approaches. Whether or
not a specific approach is adequate depends much on the
type and quality of available data. Regulatory decision-
makers, guideline developers, or users of the evidence are
likely to perceive the ease of use and ease of interpretation
of quantitative approaches very differently because of dif-
ferent levels of methodological expertise or different per-
spectives. Therefore, we believe that our framework for
organizing quantitative approaches is complementary to,
rather than competing with, what Lynd and others have
proposed. The frameworks proposed by our team, Lynd,and others support a systematic, well-structured, and
transparent process for reducing the multidimensionality
of a benefit-harm assessment.
Our review showed that current quantitative approaches
for benefit-harm assessment might need some further
development. Firstly, many quantitative approaches iden-
tified here focus on binary outcomes that occur just once,
with or without consideration of time to event. Current
methods need extensions that also consider different
types of data. Some patient-important outcomes, such as
quality of life or symptoms, cannot be expressed appro-
priately as binary outcomes without substantial loss of
information. Some benefit and harm events can occur
several times so that the number of events per person-
time needs to be considered rather than the proportion
of persons with at least one event. Secondly, uncertainty
estimates for the benefit and harm comparison metric
(e.g. 95 percent confidence or credible intervals) are
likely to be of key importance for decisionmakers and
organizations making treatment recommendations.
Researchers do not commonly report estimates of uncer-
tainty that arises from sampling variability. In addition,
none of the methods considers the joint distribution of
benefit and harm outcomes. Researchers should develop
statistical methods for considering joint distributions
when estimating standard errors for benefit-harm com-
parison metrics. For systematic reviews it would be valu-
able to develop approaches for making assumptions
about joint distributions because covariance matrices are
rarely available from reports of primary studies and it
may be challenging to request them from authors of pri-
mary studies. Thirdly, researchers should develop sys-
tematic approaches for sensitivity analyses that assess
the influence of the various assumptions commonly
made. One approach would be to agree on a list of
standard sensitivity analyses for key aspects of a benefit-
harm assessment. For example, data for estimating base-
line risks (e.g. probability of outcome without treatment)
can come from different sources (e.g. surveillance data,
observational studies, and placebo arms of randomized
trials). The best available evidence on treatment effects
may sometimes come from single randomized trial or ob-
servational study rather than from meta-analyses.
Researchers may be able to derive patient preferences by
different eliciting techniques. A systematic outline of
these options (the choices for the primary analysis and
for sensitivity analyses), would make benefit-harm assess-
ments transparent and give users of the evidence a sense
for how sensitive the results are to different assumptions.
A strength of our review is the collaborative effort of
clinicians, epidemiologists, and statisticians that helped us
to develop a comprehensive framework for characterizing
quantitative approaches for benefit-harm assessment.
Some may perceive it as a limitation that we did not
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talized on an existing, recent review [5]. Also, we used an
iterative approach of developing a framework rather than
following a more standardized approach, such as Delphi-
like procedures, to identify important characteristics of
quantitative approaches for benefit-harm assessment. How-
ever, a more standardized approach also has its limitations
because it does not allow discussing intertwined issues or
considering different perspectives of an interdisciplinary re-
search group in great depth.
We developed a framework for the use of quantitative
approaches for benefit-harm assessment that can help
researchers select specific approaches. We do not make
recommendations for or against specific approaches. It is
too early to make such recommendations because of the
lack of evidence from studies that directly compare quanti-
tative approaches applied to a specific question. The ad-
equacy of approaches depends on the specific benefit-harm
question and on the amount and quality of data that deter-
mine how justifiable certain assumptions are. In some situa-
tions, there may be a single approach that appears to be
most appropriate. But commonly, there will be several
approaches that are reasonable options given the question,
the goal of the benefit-harm assessment, and the available
data. In such situations, we suggest that investigators use
several approaches, as commonly used in other areas
[43,44], which acknowledges that none of them is perfect
and based on some assumptions. The confidence in the
results of benefit-harm assessments then depends on the
extent to which different approaches arrive at similar
results, and how useful they are to end-users. Evidence from
studies applying multiple approaches to the same benefit-
harm question, together with recognition of their advan-
tages and disadvantages, would make it possible to identify
approaches that are consistently superior over others, and
to develop recommendations for specific approaches.
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